HEPATOTOXICITY ASSOCIATED WITH SUSTAINED-RELEASE NIACIN

被引:60
作者
DALTON, TA [1 ]
BERRY, RS [1 ]
机构
[1] UNIV ALABAMA,SCH MED,DEPT MED,BIRMINGHAM,AL 35233
关键词
D O I
10.1016/0002-9343(92)90689-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Niacin (nicotinic acid) is a widely used agent in the treatment of hyperlipidemias characterized by elevated low-density lipoprotein and very-low- density lipoprotein. The tendency of the conventional crystalline niacin to cause flushing has limited its use in many patients. Sustained-release (SR) niacin preparations are increasingly utilized due to a lower incidence of flushing and convenient dosing frequency. Although gastrointestinal and hepatotoxic side effects are common to both formulations, they are more frequent and occasionally more severe with the SR preparations. We describe a patient who developed an acute illness characterized by hypothermia, hypotension, metabolic acidosis, and severe hepatic dysfunction 2 days after substitution of an SR preparation for a previously well-tolerated crystalline niacin.
引用
收藏
页码:102 / 104
页数:3
相关论文
共 13 条
[1]   CURRENT THERAPY FOR HYPERCHOLESTEROLEMIA [J].
BLUM, CB ;
LEVY, RI .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (24) :3582-3587
[2]  
CHRISTENSEN NA, 1961, JAMA-J AM MED ASSOC, V177, P76
[3]   NICOTINIC ACID-INDUCED FULMINANT HEPATIC-FAILURE [J].
CLEMENTZ, GL ;
HOLMES, AW .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1987, 9 (05) :582-584
[4]   NIACIN-INDUCED HEPATITIS - A POTENTIAL SIDE-EFFECT WITH LOW-DOSE TIME-RELEASE NIACIN [J].
ETCHASON, JA ;
MILLER, TD ;
SQUIRES, RW ;
ALLISON, TG ;
GAU, GT ;
MARTTILA, JK ;
KOTTKE, BA .
MAYO CLINIC PROCEEDINGS, 1991, 66 (01) :23-28
[5]   ISCHEMIC HEPATITIS - CLINICAL-FEATURES, DIAGNOSIS AND PROGNOSIS [J].
GIBSON, PR ;
DUDLEY, FJ .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1984, 14 (06) :822-825
[6]   NIACIN REVISITED - CLINICAL OBSERVATIONS ON AN IMPORTANT BUT UNDERUTILIZED DRUG [J].
HENKIN, Y ;
OBERMAN, A ;
HURST, DC ;
SEGREST, JP .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 (03) :239-246
[7]   RECHALLENGE WITH CRYSTALLINE NIACIN AFTER DRUG-INDUCED HEPATITIS FROM SUSTAINED-RELEASE NIACIN [J].
HENKIN, Y ;
JOHNSON, KC ;
SEGREST, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (02) :241-243
[8]   CONTRASTING EFFECTS OF UNMODIFIED AND TIME-RELEASE FORMS OF NIACIN ON LIPOPROTEINS IN HYPERLIPIDEMIC SUBJECTS - CLUES TO MECHANISM OF ACTION OF NIACIN [J].
KNOPP, RH ;
GINSBERG, J ;
ALBERS, JJ ;
HOFF, C ;
OGILVIE, JT ;
WARNICK, GR ;
BURROWS, E ;
RETZLAFF, B ;
POOLE, M .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1985, 34 (07) :642-650
[9]   FULMINANT HEPATIC-FAILURE AFTER INGESTION OF SUSTAINED-RELEASE NICOTINIC-ACID [J].
MULLIN, GE ;
GREENSON, JK ;
MITCHELL, MC .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (03) :253-255
[10]   SEVERE LIVER DYSFUNCTION DURING NICOTINIC ACID THERAPY [J].
PARDUE, WO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1961, 175 (02) :137-&